7/27/2019 Ivabradine for OI
2/2
2. Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia
syndrome: a concise
guide to diagnosis and management. J Cardivasc Electrophysiol
2006;17:10812.
3. Furlan R, Jacob G, Snell M, Robertson D, Porta A, Harris P et
al. Chronic ortho-
static intolerance: a disorder with discordant cardiac and
vascular sympathetic
control. Circulation 1998;98:21549.
4. Shibao C, Arzubioga C, Roberts LJ, Raj S, Black B, Harris P
et al. Hyperadrenergic
postural tachycardia syndrome in mast cell activation disorders.
Hypertension
2005;45:38590.
5. Moya A, Sutton R, Ammirati F, Blanc J-J, Brignole M, Dahm JB
et al. Guidelines for
the diagnosis and treatment of syncope (verion 2009). Eur Heart
J 2009;30:
263171.
6. Melby DP, Lu F, Sakaguchi S, Zook M, Benditt DG. Increased
impedance to inspi-
ration ameliorates hemodynamic changes associated with movement
to upright
posture in orthostatic hypotension. A randomized pilot study.
Heart Rhythm
2007;4:12835.
7. Carew S, Connor MO, Cooke J, Conway C, Sheehy A, Costelloe A
et al.
A review of postural orthostatic tachycardia syndrome. Europace
2009;
11:1825.
8. McDonald C, Frith J, Newton JL. Single centre experience of
ivabradine
in postural orthostatic tachycardia syndrome. Europace
2011;13:
427430.
9. Servier Laboratories Limited Procorolan Summary of Product
Characteristics.
http://www.medicines.org.uk/emc/medicine/171882010.
10. Fox K, Ford I, Steg PG, Tendera M, Ferrari R on behalf of
the BEAUTIFUL Inves-
tigators. Ivabradine for patients with stable coronary artery
disease and left ven-
tricular systolic dysfunction (BEAUTIFUL): a randomised
double-blind, placebo
controlled trial. Lancet 2008;372:80818.
11. Sutton R, Petersen M, Brignole M, Raviele A, Menozzi C,
Giani P. Proposed classi-
fication for tilt induced vasovagal syncope. Eur J Cardiac
Pacing Electrophysiol 1992;
2:1803.
Editorial 307
